Proton Pump Inhibitors and Weight Gain
Long-term proton pump inhibitors are linked with weight gain in observational studies - about 3.5 kg over two years in one reflux cohort - and with slower weight loss after gastric bypass.
Plain English
Patient-Friendly Explanation
Proton pump inhibitors are among the most prescribed medicines in the world. Their names end in -prazole: omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole. They shut down the tiny pumps in the stomach lining that produce acid, which makes them very effective for reflux, inflammation of the stomach and ulcer prevention, and they are routinely prescribed for a period after weight-loss surgery. Short courses are generally safe and, for many people, transformative. The question that matters here is what happens over years. In one study of fifty-two patients with reflux who took a maintenance dose for an average of about two years, body weight rose from an average of fifty-six to nearly fifty-nine kilograms - a gain of 3.5 kilograms, or about six per cent - and it rose in seven out of ten of them, while a matched group of people without reflux did not change. A separate analysis of more than three thousand adults in a national health survey found that men taking a proton pump inhibitor had gained about one and a half kilograms more over the previous year than men who were not, with no significant difference in women. Other work has found that acid suppression was associated with poorer weight loss after gastric bypass. It is important to be careful about what these studies do and do not show: they show an association, not proof of cause, and reflux itself is more common in people who carry extra weight. Proposed explanations include changes to the bacteria in the gut - acid suppression produces some of the largest shifts in gut bacteria of any common medicine - and the fact that controlling reflux removes the discomfort that naturally leads people to eat smaller meals. The practical response is not to stop a medicine that is needed. It is to have the prescription reviewed: whether it is still required, whether the dose can be reduced, and whether it can be stopped gradually, since stopping abruptly can cause a rebound surge of acid. Weight gain on its own is not a reason to stop, but it is a good reason to ask the question at the next consultation.
Medical
Clinical Definition
Proton pump inhibitors are substituted benzimidazoles that irreversibly inhibit the gastric H+/K+-ATPase of parietal cells, suppressing basal and stimulated acid secretion; they are indicated for gastro-oesophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication regimens, non-steroidal anti-inflammatory drug gastroprotection, and routinely for a defined period after bariatric surgery. Evidence linking them to weight change is observational. In a prospective study of 52 patients with gastro-oesophageal reflux disease on maintenance therapy for a mean of 2.2 years (range 0.8-5.7) compared with 58 sex- and age-matched controls, body weight rose from 56.4 +/- 10.4 kg to 58.6 +/- 10.8 kg (p<0.0001) and body mass index from 23.1 +/- 3.1 to 24.0 +/- 3.1 kg/m2 (p<0.001), with a mean gain of 3.5 kg (6.2 per cent of baseline) in 37 of 52 patients (71 per cent) and weight loss in only 6 (12 per cent); controls showed no change. In a cross-sectional analysis of 3,073 adults in NHANES 2005-2006, male proton pump inhibitor users had gained 1.52 +/- 0.59 kg over the preceding year compared with non-users (p=0.021), with no significant difference in women and no detectable difference in reported energy intake or physical activity markers, leaving the mechanism unexplained by energy balance. Acid suppression has also been associated with suboptimal weight loss after laparoscopic Roux-en-Y gastric bypass. The principal mechanistic hypothesis is drug-induced dysbiosis: proton pump inhibitors produce the largest and most variable inter-individual change in gut microbiota of the commonly used drug classes, four weeks of esomeprazole increases faecal Streptococcus and may reduce short-chain fatty acid production, and similar microbial shifts have been linked with altered energy harvest. Confounding is substantial, since reflux prevalence rises with body mass index and patients on long-term acid suppression are often older and carry more comorbidity, and no randomised trial has tested the question. Long-term use is independently associated with hypomagnesaemia, vitamin B12 deficiency, increased fracture risk, Clostridioides difficile infection and interstitial nephritis, so periodic review is recommended in its own right. Deprescribing studies show that a substantial proportion of long-term users can step down or stop with a tapering plan.
Key Insight
Why It Matters
A proton pump inhibitor is usually started for a good reason and often continued by habit; if weight is creeping up and the medicine is no longer clearly needed, that is a conversation for the next review rather than a reason to stop it alone.
Sources
Reviewed against standard medical references.
Medically reviewed by
Family Physician & Registered Acupuncturist, Accord Medical Clinic. MBBS (NUS), Graduate Diploma in Family Medicine (NUS), Graduate Diploma in Acupuncture (Singapore College of TCM).
Last reviewed: October 2026
This page is general health education, not medical advice. Whether any treatment is appropriate for you is a decision made in consultation after assessment.
